Clinical trials: Disease, Acute
COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
- Trial name
- NCT04389671
- Testing
- Lucinactant
- Where
- 11 sites in United States, Argentina
- Volunteers
- 20 people
- Sponsor
- Windtree Therapeutics
Acute Myeloid Leukemia
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT03671564
- Testing
- Milademetan
- Where
- 8 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Hematologic Malignancies
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.
- Trial name
- NCT01344707
- Testing
- 4SC-202
- Where
- 3 sites in Germany
- Volunteers
- 36 people
- Sponsor
- 4SC AG
Acute Ischemic Stroke
Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)
The main objective of this study is to document that the thrombectomy catheter (Rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are…
- Trial name
- NCT01895634
- Testing
- Rev-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Acute Alcoholic Hepatitis
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day…
- Trial name
- NCT01471028
- Testing
- ELAD treatment, Standard of care (Control)
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 203 people
- Sponsor
- Vital Therapies, Inc.
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of…
- Trial name
- NCT03030612
- Testing
- ARGX-110, AZA
- Where
- 7 sites in France, Switzerland
- Volunteers
- 38 people
- Sponsor
- OncoVerity, Inc.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease
- Trial name
- NCT01854567
- Testing
- Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units.
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mesoblast, Ltd.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Acute Myeloid Leukemia
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia
The primary objectives of this study are: 1. To evaluate whether the addition of amifostine will allow for the safe administration of idarubicin at a dose of 21 mg/m² in combination with standard-dose ara-C in older patients with…
- Trial name
- NCT00086099
- Testing
- Idarubincin and Amufostine (Ethyol), Idarubincin
- Where
- 19 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- MedImmune LLC
Acute Coronary Syndrome (ACS)
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined…
- Trial name
- YingLong (NCT02430493)
- Where
- 15 sites in China
- Volunteers
- 1,066 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction, Congestive Heart Failure
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction
The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for the prevention of ventricular remodeling and congestive heart failure when administered to subjects who had successful percutaneous…
- Conditions
- Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
- Trial name
- PRESERVATION-1 (NCT01226563)
- Testing
- IK-5001, Saline Solution
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 303 people
- Sponsor
- Bellerophon BCM LLC
SARS-CoV Infection
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.
- Trial name
- NCT04327804
- Testing
- Odd/Even birth year intervention groups
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- UnitedHealth Group
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01431339
- Testing
- IV Dalbavancin, Vancomycin/Linezolid
- Where
- 137 sites in United States, Bulgaria and 12 more
- Volunteers
- 739 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Acute Ischemic Stroke
Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke
The study is designed as a multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy and safety of TTYP01 tablets in the treatment of acute ischemic stroke.
- Trial name
- NCT06648304
- Testing
- TTYP01 tablets
- Where
- China
- Volunteers
- 614 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Venous Thromboembolism
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE.
- Trial name
- NCT02596230
- Where
- 222 sites in United States, Argentina and 35 more
- Volunteers
- 7,797 people
- Sponsor
- Boehringer Ingelheim
Relapsed/Refractory Acute Myeloid Leukemia
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection.
- Trial name
- NCT06541444
- Testing
- NK520
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Chronic Kidney Diseases, Acute Kidney Injury
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone.
- Conditions
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- Trial name
- NAD agent (NCT06866236)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Ebima Clifford Okundaye
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.